A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants
Condition: Healthy Volunteers
Intervention: TAK-788
Intervention description: TAK-788 Capsule.
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 14.0
Sex: All
Minimum age: 19 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug Therapy

Summary:

      The purpose of this study is to characterize the effect of a high-fat meal on the PK of
      TAK-788 administered in healthy participants.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Continuous non-smoker who has not used nicotine-containing products for at least 20
             years prior to the first dosing and throughout the study, based on participant
             self-reporting.

          2. Body mass index (BMI) greater than or equal to (>=) 18.5 and less than or equal to
             (<=) 30.0 kilogram per square meter (kg/m^2), at screening.

          3. Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs, or electrocardiogram (ECGs), as deemed
             by the Investigator or designee.

        Exclusion Criteria:

          1. History of any illness (including hyperlipidemia and diabetes since high fat meal is
             required) that, in the opinion of the Investigator or designee, might confound the
             results of the study or poses an additional risk to the participant by their
             participation in the study.

          2. History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dosing.

          3. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs
             or related compounds.

          4. History or presence of any previous lung disease and/or current lung infection.

          5. Positive urine drug or alcohol results at screening or first check-in.

          6. Positive results at screening for Human immunodeficiency virus (HIV), Hepatitis B
             surface antigen (HBsAg), or Hepatitis C virus (HCV).

          7. Positive test result for active coronavirus disease 2019 (COVID-19).

          8. Seated blood pressure is less than (<) 90/40 millimeter of mercury of mercury (mmHg)
             or greater than 140/90 mmHg at screening.

          9. Seated heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at
             screening.

         10. QT interval corrected for heart rate using Fridericia's formula (QTcF) interval is
             greater than (>) 460 millisecond (msec) (males) or >470 msec (females) or ECG findings
             are deemed abnormal with clinical significance by the Investigator or designee at
             screening.

         11. Creatinine clearance <90 milliliter per minute (mL/min) at screening (calculated using
             the Cockcroft-Gault formula).

         12. Unable to refrain from or anticipates the use of:

             o Any drug, including prescription and non-prescription medications, herbal remedies,
             or vitamin supplements within 14 days prior to the first dosing and throughout the
             study. Medication listed as part of acceptable birth control methods will be allowed.
             Thyroid hormone replacement medication may be permitted if the participant has been on
             the same stable dose for the immediate 3 months prior to the first dosing.

             Acetaminophen (up to 2 gram per 24 hour period) may be permitted during the study,
             only after initial dosing, if necessary, to treat adverse events (AEs).

             o Any drugs known to be inhibitors or inducers of Cytochrome P450 (CYP3A) enzymes
             and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the
             first dosing and throughout the study.

         13. Has been on a diet incompatible with the on-study diet, in the opinion of the
             Investigator or designee, within the 30 days prior to the first dosing and throughout
             the study.

         14. Donation of blood or significant blood loss within 56 days prior to the first dosing.

         15. Plasma donation within 7 days prior to the first dosing.